Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 9:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Heart Hypertrophy Clear all
Completed Not applicable Interventional

Vitamin D Therapy to Reduce Cardiac Damage Among Vulnerable Hypertensive Patients

NCT01360476
View directory record Official record
Conditions
Hypertension, Left Ventricular Hypertrophy
Interventions
cholecalciferol (Vitamin D), Placebo
Dietary Supplement
Lead sponsor
Wayne State University
Other
Eligibility
30 Years to 74 Years
Enrollment
354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 8, 2015 · Synced Jun 10, 2026, 9:27 PM EDT
Not listed Not applicable Interventional

Perfusion Imaging With Myocardial Contrast Echocardiography in HCM

NCT02560467
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy
Interventions
Echo and myocardial contrast echocardiography perfusion imaging
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
19 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 5, 2019 · Synced Jun 10, 2026, 9:27 PM EDT
Completed No phase listed Observational

Evaluation of Patients With Known or Suspected Heart Disease

NCT00001313
View directory record Official record
Conditions
Peripheral Artery Disease, Coronary Disease, Diabetes and Heart Failure, Dilated Cardiomyopathy, Heart Failure, Renal Artery Stenosis, Pulmonary Hypertension
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2009
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jun 10, 2026, 9:27 PM EDT
Completed Phase 3 Interventional Results available

The PRIMO Study: Paricalcitol Capsules Benefits Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease Stage 3/4

NCT00497146
View directory record Official record
Conditions
Chronic Kidney Disease, Left Ventricular Hypertrophy
Interventions
paricalcitol, placebo
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years and older
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
30
States / cities
Phoenix, Arizona • Tempe, Arizona • San Diego, California + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2013 · Synced Jun 10, 2026, 9:27 PM EDT
Completed Phase 4 Interventional Results available

Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.

NCT02970669
View directory record Official record
Conditions
Heart Failure, Reduced Ejection Fraction
Interventions
sacubitril/valsartan (LCZ696), enalapril, matching placebo sacubitril/valsartan (LCZ696), matching placebo enalapril
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
23
States / cities
Fort Payne, Alabama • Beverly Hills, California • Stockton, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2021 · Synced Jun 10, 2026, 9:27 PM EDT
Completed Phase 3 Interventional Results available

Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essential Hypertension

NCT00219141
View directory record Official record
Conditions
Hypertension, Left Ventricular Hypertrophy, Overweight
Interventions
Aliskiren 150/300 mg, Losartan 50/100 mg, Aliskiren placebo, Losartan 50/100 mg placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated May 25, 2011 · Synced Jun 10, 2026, 9:27 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

US Benchmarking Clinical Study

NCT07215715
View directory record Official record
Conditions
HFpEF - Heart Failure With Preserved Ejection Fraction, HFmrEF, ATTR-CM (Transthyretin Amyloid Cardiomyopathy), Left Ventricular Hypertrophy, Cardiac Amyloidosis
Interventions
Not listed
Lead sponsor
eMyosound SAS
Industry
Eligibility
60 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 19, 2025 · Synced Jun 10, 2026, 9:27 PM EDT
Not listed No phase listed Observational

Cardiac Biomarkers in Pediatric Cardiomyopathy (PCM Biomarkers)

NCT01873976
View directory record Official record
Conditions
Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy
Interventions
Not listed
Lead sponsor
Wayne State University
Other
Eligibility
Up to 20 Years
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
12
States / cities
Aurora, Colorado • Chicago, Illinois • Boston, Massachusetts + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2020 · Synced Jun 10, 2026, 9:27 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Biomarkers in Aortic Stenosis - B.A.S.S.

NCT01334801
View directory record Official record
Conditions
Aortic Stenosis, Disorder of Prosthetic Cardiac Valve, Aortic Valve Insufficiency, Mitral Valve Insufficiency, Hypertrophic Cardiomyopathy, Tricuspid Valve Insufficiency
Interventions
Blood Draw
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years and older
Enrollment
378 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2020
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 4, 2022 · Synced Jun 10, 2026, 9:27 PM EDT
Terminated Not applicable Interventional

Effect of Personalized Accelerated Pacing in Symptomatic Patients With Non-Obstructive Hypertrophic Cardiomyopathy

NCT06775886
View directory record Official record
Conditions
Non-obstructive Hypertrophic Cardiomyopathy, Hypertrophic Cardiomyopathy
Interventions
myPACE+ algorithm
Other
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Jun 10, 2026, 9:27 PM EDT
Enrolling by invitation Phase 2Phase 3 Interventional

Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM

NCT04848506
View directory record Official record
Conditions
Symptomatic Hypertrophic Cardiomyopathy (HCM)
Interventions
Aficamten (5 - 20 mg)
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years to 85 Years
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
52
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Jun 10, 2026, 9:27 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of Coronary Luminal Diameter Enlargement With Emerge™ 1.20 mm PTCA Dilatation Catheter

NCT01635881
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Emerge™ 1.20 mm PTCA Dilatation Catheter
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 5, 2013 · Synced Jun 10, 2026, 9:27 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Imaging Histone Deacetylase in the Heart

NCT03549559
View directory record Official record
Conditions
Heart Failure With Normal Ejection Fraction, Left Ventricular Hypertrophy, Aortic Valve Stenosis, Diabetes
Interventions
11C-Martinostat, PET-MRI
Drug · Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 21, 2025 · Synced Jun 10, 2026, 9:27 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM

NCT05767346
View directory record Official record
Conditions
Obstructive Hypertrophic Cardiomyopathy (oHCM)
Interventions
Aficamten (CK-3773274) (5 mg, 10 mg, 15 mg and 20 mg), Placebo to match aficamten, Metoprolol succinate (50 mg, 100 mg, 150 mg and 200 mg), Placebo to match metoprolol succinate
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years to 85 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
28
States / cities
Anchorage, Alaska • Phoenix, Arizona • La Jolla, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Jun 10, 2026, 9:27 PM EDT
Terminated Phase 3 Interventional Results available

Hypertension in Hemodialysis Patients (Aim 3)

NCT00582114
View directory record Official record
Conditions
Hemodialysis, Hypertension, Left Ventricular Hypertrophy
Interventions
Lisinopril, Atenolol
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 17, 2016 · Synced Jun 10, 2026, 9:27 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Advancing Understanding of Transportation Options

NCT04141891
View directory record Official record
Conditions
Diabetic Retinopathy, Macular Degeneration, Glaucoma, Retinitis Pigmentosa, Vision Disorders, Acute Coronary Syndrome, Implantable Defibrillator User, Congestive Heart Failure, Hypertrophic Obstructive Cardiomyopathy, Orthostatic Hypotension, Syncope, Presyncope, Narcolepsy, Dementia, Multiple Sclerosis, Parkinson Disease, Brain Injuries, Spinal Cord Injuries, Stroke, Vertigo, Dizziness, Seizures, Substance Use, Insulin Dependent Diabetes Mellitus, Arthritis, Foot--Abnormalities, Chronic Obstructive Pulmonary Disease, Obstructive Sleep Apnea, End Stage Renal Disease, Sleep Apnea, Insomnia, Restless Legs Syndrome
Interventions
Driving Decision Aid, Older Drivers Website
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
529 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
3
States / cities
La Jolla, California • Aurora, Colorado • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 20, 2025 · Synced Jun 10, 2026, 9:27 PM EDT
Active, not recruiting No phase listed Observational

HCMR - Novel Markers of Prognosis in Hypertrophic Cardiomyopathy

NCT01915615
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy
Interventions
None - this is an observational study
Other
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 65 Years
Enrollment
2,750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
17
States / cities
New Haven, Connecticut • Chicago, Illinois • Baltimore, Maryland + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2024 · Synced Jun 10, 2026, 9:27 PM EDT
Completed Phase 2 Interventional Results available

Extension Study of Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Previously Enrolled in PIONEER

NCT03496168
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy
Interventions
mavacamten
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
4
States / cities
Scottsdale, Arizona • New Haven, Connecticut • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2025 · Synced Jun 10, 2026, 9:27 PM EDT
Completed Phase 2 Interventional

Pirfenidone to Treat Hypertrophic Cardiomyopathy

NCT00011076
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy
Interventions
Pirfenidone
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jun 10, 2026, 9:27 PM EDT
Recruiting No phase listed Observational

Effect of Mavacamten Treatment on Coronary Flow Reserve in oHCM

NCT06023186
View directory record Official record
Conditions
Obstructive Hypertrophic Cardiomyopathy
Interventions
mavacamten
Drug
Lead sponsor
Michael Ayers
Other
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 5, 2024 · Synced Jun 10, 2026, 9:27 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Exercise Study Including Patients With Hypertrophic Cardiomyopathy

NCT01165749
View directory record Official record
Conditions
Cardiomyopathy, Hypertrophic
Interventions
stop exercising
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 19, 2010 · Synced Jun 10, 2026, 9:27 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Human Experimental Models of Pain (HEMP)

NCT07549490
View directory record Official record
Conditions
Acute Pain
Interventions
Placebo, Naproxen, Pregabalin
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years to 100 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Jun 10, 2026, 9:27 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

UTSW HP [13-C] Pyruvate Injection in HCM

NCT03057002
View directory record Official record
Conditions
Cardiomyopathy, Hypertrophic, Dilated Cardiomyopathy, Duchenne Muscular Dystrophy, Cardiac Sarcoidosis, Becker Muscular Dystrophy, Heart Failure With Preserved Ejection Fraction, Heart Failure With Reduced Ejection Fraction
Interventions
Hyperpolarized 13C-Pyruvate
Diagnostic Test
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Jun 10, 2026, 9:27 PM EDT
Completed No phase listed Observational

Effects of Highly Active Anti-Retroviral Therapy on Cardiovascular Health in Infants of HIV-Infected Mothers

NCT00253682
View directory record Official record
Conditions
Cardiovascular Diseases, Heart Diseases, Atherosclerosis, HIV Infections, Cardiomyopathy, Hypertrophic
Interventions
Not listed
Lead sponsor
University of Miami
Other
Eligibility
Up to 2 Years
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
5
States / cities
Miami, Florida • Chicago, Illinois • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2014 · Synced Jun 10, 2026, 9:27 PM EDT